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p90 Ribosomal S6 kinases play a significant role in early gene regulation
in the cardiomyocyte response to Gq-protein-coupled receptor stimuli,
endothelin-1 and α1-adrenergic receptor agonists
Emre AMIRAK, Stephen J. FULLER, Peter H. SUGDEN and Angela CLERK1
School of Biological Sciences, University of Reading, Whiteknights, Reading RG6 6BX, U.K.
ERK1/2 (extracellular-signal-regulated kinase 1/2) and their
substrates RSKs (p90 ribosomal S6 kinases) phosphorylate
different transcription factors, contributing differentially to
transcriptomic profiles. In cardiomyocytes ERK1/2 are required
for >70% of the transcriptomic response to endothelin-
1. In the present study we investigated the role of RSKs
in the transcriptomic responses to the Gq-protein-coupled
receptor agonists endothelin-1, phenylephrine (a generic α1-
adrenergic receptor agonist) and A61603 (α1A-adrenergic receptor
selective). Phospho-ERK1/2 and phospho-RSKs appeared in
cardiomyocyte nuclei within 2–3 min of stimulation (endothelin-
1>A61603≈phenylephrine). All agonists increased nuclear
RSK2, but only endothelin-1 increased the nuclear RSK1 content.
PD184352 (inhibits ERK1/2 activation) and BI-D1870 (inhibits
RSKs) were used to dissect the contribution of RSKs to
the endothelin-1-responsive transcriptome. Of the 213 RNAs
up-regulated after 1 h, 51% required RSKs for their up-
regulation, whereas 29% required ERK1/2 but not RSKs. The
transcriptomic response to phenylephrine overlapped with, but
was not identical with, endothelin-1. As with endothelin-1,
PD184352 inhibited the up-regulation of most phenylephrine-
responsive transcripts, but the greater variation in the effects of
BI-D1870 suggests that differential RSK signalling influences
global gene expression. A61603 induced similar changes in RNA
expression in cardiomyocytes as phenylephrine, indicating that
the signal was mediated largely through α1A-adrenergic receptors.
A61603 also increased expression of immediate early genes in
perfused adult rat hearts and, as in cardiomyocytes, up-regulation
of the majority of genes was inhibited by PD184352. PD184352
or BI-D1870 prevented the increased surface area induced by
endothelin-1 in cardiomyocytes. Thus RSKs play a significant
role in regulating cardiomyocyte gene expression and hypertrophy
in response to Gq-protein-coupled receptor stimulation.
Key words: α1-adrenergic receptor, cardiomyocyte, endothelin,
mitogen-activated protein kinase (MAPK), p90 ribosomal S6
kinase (p90 RSK), transcriptomics.
INTRODUCTION
The ERK1/2 (extracellular-signal-regulated kinase 1/2) cascade
plays a major role in the global regulation of gene expression
[1]. ERK1/2, the prototypic MAPKs (mitogen-activated protein
kinases), are activated by dual phosphorylation of threonine
and tyrosine residues within a T-E-Y motif, and they then
phosphorylate substrates in both the cytoplasmic and nuclear
compartments [2]. In the nucleus ERK1/2 phosphorylate
nuclear-localized transcription factors (e.g. Elk1) to regulate
their transactivating activities and/or association with other
transcription factors, thus directly influencing the transcription of
specific genes. ERK1/2 also phosphorylate downstream protein
kinases including RSKs (p90 ribosomal S6 kinases) [3,4]. RSKs
are ubiquitously expressed and are generally localized in the
cytoplasm in unstimulated cells, but mitogenic stimulation results
in the nuclear translocation of three of the four RSK isoforms
(RSK1, RSK2 and RSK3). Like ERK1/2, RSKs phosphorylate
cytoplasmic and nuclear substrates. However, the preferred
phosphorylation motifs for ERK1/2 (proline-directed kinases)
and RSKs (which phosphorylate serine/threonine residues
within an R-X-R-X-X-S/T motif) differ and they phosphorylate
different substrates. ERK1/2 also activate MSKs (mitogen- and
stress-activated protein kinases), kinases related to RSKs [3].
MSKs are predominantly nuclear-localized and are involved in
transcriptional regulation. A third family of downstream kinase
substrates of ERK1/2 are MNKs (MAPK-interacting kinases) [3].
Although MNK1/2 may traffic into the nucleus they primarily
target components of the translational apparatus.
Mammalian cardiomyocytes, the contractile cells of the heart,
are terminally differentiated, withdrawing from the cell cycle
around the time of birth. In response to a demand for increased
power output (e.g. following the death of adjacent cells as
a result of myocardial infarction or in hypertensive states),
cardiomyocytes increase in size and myofibrillar content, adapting
the components of the contractile apparatus and modulating their
Abbreviations used: AMPKα, AMP-activated protein kinase α; AR, adrenergic receptor; Areg, amphiregulin; Atf3, activating transcription factor 3;
BH-MTC, Benjamini and Hochberg multiple testing correction; CREB, cAMP-response-element-binding protein; Dusp, dual-specificity phosphatase; Egr,
early growth response; ERK1/2, extracellular-signal-regulated kinase 1/2; ET-1, endothelin-1; FDR, false discovery rate; Fosb, FBJ murine osteosarcoma
viral oncogene homologue B; Gapdh, glyceraldehyde 3-phosphate dehydrogenase; GSK3α/β, glycogen synthase kinase 3α/β; Has, hyaluronan synthase;
IL11, interleukin 11; Klf, Kru¨ppel-like factor; Lif, leukaemia inhibitory factor; MAPK, mitogen-activated protein kinase; MKK, MAPK kinase; MNK, MAPK-
interacting protein kinase; MSK, mitogen- and stress-activated protein kinase; NPE, nuclear protein-enriched; Nr4a, nuclear receptor subfamily 4, group
A; Olr1, oxidized low-density lipoprotein (lectin-like) receptor 1; PE, phenylephrine; PKB, protein kinase B; Plk2, polo-like kinase 2; Ptgs2, prostaglandin-
endoperoxide synthase 2, qPCR, quantitative PCR; Rgs2, regulator of G-protein signalling 2, 24 kDa; RSK, ribosomal S6 kinase; Sik1, salt-inducible kinase
1; SNK, Student–Newman–Keuls.
1 To whom correspondence should be addressed (email a.clerk@reading.ac.uk).
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metabolism (i.e. they undergo hypertrophic growth). ERK1/2
signalling is associated with cardiomyocyte hypertrophy. Thus
hypertrophic stimuli, such as ET-1 (endothelin-1) and α1-AR
(adrenergic receptor) agonists, activate the ERK1/2 cascade in
cardiomyocytes, and overexpression of constitutively activated
components of the cascade induce aspects of the response in
isolated cardiomyocytes [5]. Furthermore, small-molecule or
genetic inhibition of the cascade prevents hypertrophy [6–8].
In vivo studies in genetically modified mice highlight further the
importance of ERK1/2 signalling in the heart [9–11]. However,
none of these studies clearly establishes how ERK1/2 elicit their
effects.
Biochemical studies in neonatal rat cardiomyocytes, place
dually phosphorylated (i.e. activated) ERK1/2 in the nucleus
within 2 min of stimulation with ET-1 [12]. ERK1/2
phosphorylate DNA-binding transcription factors, including
GATA4 (GATA-binding protein 4) and Elk1 [5], consistent
with a role in direct transcriptional regulation [2]. Small-
molecule inhibitors of ERK1/2 signalling inhibit the increases in
expression of >70% of the mRNAs up-regulated by ET-1 [13–
15]. Presumably, activation of other signalling pathways by ET-1
(e.g. c-Jun N-terminal kinases and p38 MAPKs [2]) contributes to
the transcriptional changes, but the data suggest that the ERK1/2
cascade plays a major role in regulating cardiomyocyte gene
expression [2,5,12–15]. ET-1 is particularly potent at activating
ERK1/2. Other stimuli such as PE (phenylephrine; an α1-AR
agonist) do not activate ERK1/2 to the same degree [16] and
also activate other MAPKs [2]. It is unclear whether (although
they signal through a similar Gq-protein-coupled receptor system
[17]) ERK1/2 play as significant a role in this context. Even if
they do, since different degrees/duration of ERK1/2 signalling
can elicit profoundly different cellular responses in other cells,
the transcriptional responses to PE compared with ET-1 may still
be qualitatively different. In cardiomyocytes, as in other cells,
activated ERK1/2 in the cytoplasm phosphorylate and activate
RSKs, but the importance of RSKs in regulating cardiomyocyte
gene expression has not been explored. In the present study we
demonstrate that RSKs contribute to the changes in expression of
>50% of the RNAs up-regulated by ET-1 within 1 h (when most
changes in immediate early gene expression are detected [14]),
whereas 29% required ERK1/2, but not RSKs, for up-regulation.
We also demonstrate that the gene expression response to α1-AR
stimulation (signalling primarily through α1A-ARs) is not identical
with that of ET-1, although the signal is still predominantly
mediated by the ERK1/2 cascade. The contribution of RSKs
differs according to stimulus and this probably reflects differential
signalling to specific RSK isoforms.
EXPERIMENTAL
Cardiomyocyte cultures
Ventricles were dissected from neonatal (2–4-day-old) Sprague–
Dawley rat hearts (Harlan) and the cardiomyocytes were prepared
and plated as described previously [15]. After 18 h in medium
containing 15% (v/v) fetal bovine serum, the medium was
changed to serum-free maintenance medium for a further 24 h.
Stock solutions of agonists/inhibitors were prepared at 1000× the
working concentration and added directly to the tissue culture
medium. PD184352 (Alexis Biochemicals, Enzo Life Sciences)
and BI-D1870 (Division of Signal Transduction Therapy Unit,
University of Dundee, Dundee, U.K. and Enzo Life Sciences)
were prepared in DMSO. ET-1 (Bachem), PE (Sigma–Aldrich)
and A61603 (Tocris Bioscience) were dissolved in water.
Adult rat heart perfusions
Male 275–300 g Sprague–Dawley rats were housed and work
was undertaken in accordance with local institutional animal
care committee procedures and the U.K. Animals (Scientific
Procedures) Act 1986. Hearts were perfused retrogradely (37 ◦C
at 70 mmHg) as described previously [18]. For the experiments
with PD184352, the drug was added to the perfusate during
the 15 min equilibration period. A61603 was added at the end
of the equilibration period and all perfusions were continued
for 1 h. Hearts were ‘freeze-clamped’ between aluminium tongs
cooled in liquid nitrogen and were pulverized under liquid nitro-
gen in a pestle and mortar. The powders were stored at − 80 ◦C.
Immunoblotting
Total cardiomyocyte extracts were prepared as described
previously [15]. Cytosolic and NPE (nuclear protein-enriched)
extracts were prepared as described in [19] with the addition
of 4 μM microcystin-LR in all buffers. Samples were stored at
− 20 ◦C. Proteins were separated by SDS/PAGE (10% gels). For
ERK1/2, volumes equivalent to 2×105 or 5.3×105 cells were
used for analysis of the cytosolic or NPE fractions respectively.
For RSKs, volumes equivalent to 3×105 or 8×105 cells were
used for analysis of the cytosolic or NPE fractions respectively.
For RSK1 and RSK2, volumes equivalent to 1×106 cells were
used for analysis of the NPE fractions. Immunoblotting was
performed as described previously [15] (primary antibodies are
listed in Supplementary Table S1A at http://www.biochemj.org/
bj/450/bj4500351add.htm). Secondary antibodies conjugated to
horseradish peroxidase were from Dako (1:5000 dilution). Bands
were detected using ECL reagent and X-ray film ECL Prime
and an Imagequant 350 system or a LAS4000 mini system
(GE Healthcare). Quantification was performed using Imagequant
software. To determine relative amounts of total ERK1/2 or total
RSKs in the cytosol compared with the NPE fractions, cytosol
samples (control and 5 min ET-1 treatment) were analysed on the
same blots as the NPE fractions.
Microarray hybridizations, data analysis and qPCR (quantitative
PCR) validations
The additions of inhibitors/agonists were staggered and cells were
harvested simultaneously. To minimize variation from different
cardiomyocyte preparations, equal amounts of RNA from three
separate myocyte preparations were pooled to generate a single
sample set and three such sets were hybridized to separate
microarrays. For changes in RNA expression induced by PE
or ET-1 at 2, 4 or 24 h, RNA was extracted, labelled cRNA
was prepared and hybridization to Affymetrix rat genome 230
2.0 arrays was performed as described previously [14]. For
studies using Affymetrix rat exon 1.0 ST arrays, cardiomyocytes
were unstimulated (controls), exposed to 2 μM PD184352 or
10 μM BI-D1870 for 70 min, exposed to PE or ET-1 for 0.5
or 1 h, or exposed to PD184352 or BI-D1870 for 10 min
before the addition of ET-1 for a further 1 h. Total RNA was
provided to the NASC (Nottingham Arabidopsis Stock Centre)
for preparation and hybridization according to their protocols
(http://affymetrix.arabidopsis.info). The data were deposited in
ArrayExpress (accession numbers E-MIMR-3, E-MIMR-37,
E-MEXP-3393, E-MEXP-3394, E-MEXP-3678 and E-MEXP-
3679).
Microarray data (.CEL files) were imported into GeneSpring
12.0 (Agilent Technologies). For the Affymetrix rat genome 230
2.0 microarrays, PE and ET-1 data were imported, normalized and
analysed as described previously [15]. Probesets were selected
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with minimum raw values of 50 in all of any condition, with
>1.5-fold change at any time relative to controls and statistically
significant changes [FDR (false discovery rate)<0.05] identified
by one-way ANOVA with an SNK (Student–Newman–Keuls)
post-test, applying a BH-MTC (Benjamini and Hochberg multiple
testing correction). The data for PE and ET-1 at 24 h were
co-analysed, selecting probesets according to the same criteria.
Heatmaps were generated by hierarchical clustering on entities
using a Euclidean similarity measure and centroid linkage rule.
For the Affymetrix exon 1.0 ST microarrays, the data for
PE and ET-1 (0.5 and 1 h) with their corresponding controls
were summarized and normalized as described previously [20],
selecting probesets according to the criteria listed above. For
analysis of the effects of PD184352 or BI-D1870 on RNA
responses to ET-1, samples were imported and summarized as for
the time course analysis. For the baseline effects of the inhibitors,
probesets were selected with >1.5-fold change with PD184352 or
BI-D1870 relative to the controls. Statistically significant changes
(FDR<0.05) were identified by unpaired Student’s t test with
a BH-MTC. To identify effects of PD184352 or BI-D1870 on
the response to ET-1, probesets were selected with >1.5-fold
change with ET-1 relative to the controls (unpaired Student’s t
test with a BH-MTC). For the up-regulated RNAs, the significant
effects of PD184352 or BI-D1870 were then identified by one-
way ANOVA with an SNK post-test, applying a BH-MTC. PE data
were analysed by k-means clustering of entities using a Euclidean
similarity measure.
Validations were performed using different RNA preparations
from those used for microarray analysis. Total RNA and cDNAs
were prepared and qPCR performed as described previously [15].
The primers designed for qPCR are listed in Supplementary
Table S1(B). Values were normalized to Gapdh (glyceraldehyde
3-phosphate dehydrogenase) expression and then to the controls.
Immunostaining and planimetry
Cardiomyocytes were unstimulated (controls) or exposed to
inhibitors with and without ET-1 (24 h at 37 ◦C). Immunostaining
was performed as described previously [15] using mouse primary
monoclonal antibodies to cardiac troponin T. Cardiomyocytes
were viewed with a Zeiss Axioskop fluorescence microscope
using a ×40 objective. Digital images captured using a
Canon PowerShot G3 camera were converted into greyscale
using Adobe Photoshop 7.0. Planimetry was performed using
ImageJ (http://rsbweb.nih.gov/ij/). Cardiomyocyte surface area
was measured for an average of 51 cells per condition. The
experiment was performed four times. Mean values were taken
for each experiment and used as a single observation.
Data interpretation and statistical analysis
Graphs were constructed and statistical analysis performed
with GraphPad Prism 4.0. Unless otherwise stated, statistical
testing used one-way ANOVA with an SNK post-test.
RESULTS
Nuclear localization of activated ERK1/2 and RSKs in
cardiomyocytes
Activated ERK1/2 and RSKs translocate to the nucleus
to modulate transcription [2,4]. To examine the subcellular
localization of activated (i.e. dually phosphorylated) ERK1/2 and
RSKs, cardiomyocytes were exposed to 100 nM ET-1, 100 μM
PE (a generic α1-AR agonist activating α1A-ARs and α1B-ARs,
both being expressed in cardiomyocytes [21]) or 50 nM A61603
(selective for α1A-ARs). The concentrations were selected on the
basis of the EC50 values for activation of protein kinase Cε (acting
upstream of the ERK1/2 cascade) in cardiomyocytes (∼1 nM and
1 μM for ET-1 and PE respectively [16]) and the EC50 value
for activation of ERK1/2 by ET-1 (∼10 nM [22]). The reported
EC50 value for A61603 stimulation of α1A-ARs and α1B-ARs is
∼6 and ∼380 nM respectively [23]. We therefore selected 50 nM
A61603 for activation of α1A-ARs. Propranolol (20 μM), a β-
AR antagonist, did not enhance the stimulation of MKK (MAPK
kinase) 1/2 or ERK1/2 by PE, but inhibited the activation of
ERK1/2 signalling by 50 μM isoprenaline (Figure 1A). There
is, therefore, no inhibitory input from β-AR signalling into the
activation of ERK1/2 by PE.
Soluble cytosolic proteins (e.g. GAPDH) were separated
from an NPE fraction containing transcription factors [e.g.
CREB (cAMP-response-element-binding protein); Figure 1B]
and the levels of activated or total ERK1/2 were determined by
immunoblotting. Phospho-ERK1/2 were detected in the cytosolic
and NPE fractions following stimulation with each agonist
(Figures 1C–1E). ET-1 promoted maximal phosphorylation of
ERK1/2 within 2–3 min with similar profiles of activation in the
cytosolic or NPE fractions (Figures 1C and 1D). Since MKK1/2
(the upstream kinases for ERK1/2) localize to the cytoplasm
[24], this suggests that trafficking of activated ERK1/2 between
compartments is rapid. Quantitative assessment indicated that
24 +− 2% (mean +− S.E.M., n = 3) of the total cellular ERK1/2
protein was present in the NPE fractions of unstimulated cells
and this did not change significantly following stimulation
(Figure 1C). The time course for activation of ERK1/2 by A61603
or PE was delayed relative to and was less than that induced by
ET-1 (Figures 1C–1E). A61603 and PE induced similar responses,
indicating that PE signals predominantly through α1A-ARs to
ERK1/2.
ERK1/2 activate RSKs by phosphorylation of Thr573 in the
C-terminal kinase domain with additional phosphorylation of
Thr359/Ser363 [4]. The C-terminal kinase causes autophosphoryla-
tion of Ser380 (residue numbers relate to RSK1). ET-1 and
A61603 promoted phosphorylation of all of these sites with
maximal phosphorylation at ∼5 min (Figures 2A and 2B). The
profiles for phosphorylation were similar with both agonists.
Although the degree of phosphorylation of Thr573 started to
decline from ∼10 min, phosphorylation of Thr359/Ser363 and Ser380
was sustained over at least 20 min. As with phospho-ERK1/2,
phospho-RSKs [assessed by immunoblotting with antibodies
against phospho-RSK(Thr573)] were detected in the cytosolic
and NPE fractions following stimulation with ET-1, PE or
A61603. The time course indicated that phosphorylation of RSKs
(Figures 2C and 2D) was delayed relative to ERK1/2 (Figures 1C
and 1D) as expected. Only 4–8% of the total RSKs were present
in the NPE fractions of unstimulated cells (Figure 2D). This
increased to 34 +− 2% following stimulation with ET-1 with a
lesser increase induced by A61603 (18 +− 7%) or PE (15 +− 2%).
The time course for translocation of total RSKs to the nucleus
coincided with RSK phosphorylation, suggesting that the events
are associated. ET-1 promoted greater activation of RSKs than
A61603 or PE (Figure 2E). RSK1 and RSK2 are the preponderant
isoforms in cardiomyocytes [25]. Although all three agonists
stimulated nuclear accumulation of RSK2, only ET-1 increased
nuclear localization of RSK1 (Figures 2E–2H). Thus differential
signalling through RSKs may influence gene expression profiles.
Signalling to gene expression via RSKs
To determine the contribution of RSKs to the changes in gene
expression that occur in cardiomyocytes, we focused on ET-1
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Figure 1 Nuclear signalling of ERK1/2 in cardiomyocytes
(A) Cardiomyocytes were unstimulated (Con), exposed to 100 μM PE, 50 μM isoprenaline (ISO; 5 min) or to 20 μM propranolol (Prop; 15 min), or exposed to propranolol (10 min) before addition
of PE (Prop/PE) or isoprenaline (Prop/ISO) (5 min). Samples were immunoblotted for phospho-MKK1/2 (P-MKK1/2), total MKK1/2 (T-MKK1/2), phospho-ERK1/2 (P-ERKs) and total ERK1/2
(T-ERKs). The experiment was repeated with similar results. (B) Immunoblots of GAPDH or CREB in cytosolic (C) and NPE (N) fractions from cardiomyocytes. (C and E) Cardiomyocytes were
unstimulated (Con), or exposed to 100 nM ET-1, 100 μM PE or 50 nM A61603 for the times indicated (C) or for 5 min (E). Fractions were immunoblotted for phospho-ERK1/2 or total ERK1/2. Blots
are representative of at least three experiments with different cardiomyocyte preparations. (D) Densitometric analysis of the blots in (C). The graphs on the left-hand side show data normalized to
maximum values. The graphs on the right-hand show the relative percentage in each fraction. Results are means +− S.E.M. for three independent myocyte preparations.
and compared the effects of 2 μM PD184352 (which inhibits
ERK1/2 activation [26]) with 10 μM BI-D1870, a selective
inhibitor of RSKs [27]. The effects of BI-D1870 on the
phosphorylation of GSK3α/β (glycogen synthase kinase 3α/β;
established RSK substrates [27]) demonstrated that 10 μM was
the lowest effective concentration for inhibition of RSKs in
cardiomyocytes (Figure 3A). BI-D1870 did not affect activation
of ERK1/2 by ET-1, but (as in other cells [27]) BI-D1870 alone
activated ERK1/2, albeit to a lesser degree than ET-1 (Figure 3B).
Others report that BI-D1870 partially inhibits the activation of
PKB (protein kinase B) in the context of insulin signalling in
some cells [28]. However, PKB is not activated to any significant
extent by ET-1 [7] or α1-AR agonists (results not shown) in
cardiomyocytes. Cardiomyocytes were exposed to inhibitors
alone or ET-1 for 1 h in the absence or presence of inhibitors.
Transcriptomic changes were determined using Affymetrix rat
exon 1.0 ST arrays. PD184352 alone promoted the down-
regulation of 42 RNAs (clusters i, iii and v) and up-regulation
of eight RNAs (clusters ii and iv) (Figure 3C and Supplementary
Table S2 at http://www.biochemj.org/bj/450/bj4500351add.htm).
BI-D1870 had a greater effect promoting the down-regulation of
155 RNAs (clusters i and vi) and the up-regulation of 76 RNAs
(clusters ii, iii and vii).
To determine the role of RSKs in regulating the ET-1-
responsive transcriptome, we selected 213 RNAs up-regulated
by ET-1 after 1 h (excluding six with >3-fold change with BI-
D1870 alone). The effects of PD184352 or BI-D1870 on the
change induced by ET-1 was determined statistically (FDR<0.05)
and on the condition of 20% modulation of the response
allowing for inhibitor baseline effects (Supplementary Table
S3 at http://www.biochemj.org/bj/450/bj4500351add.htm). The
microarray data were validated by qPCR for selected mRNAs
studying the effects of inhibitors over 0.5, 1, 1.5 and 2 h.
The largest cluster (111 RNAs, cluster 1) contained RNAs
whose up-regulation was inhibited by PD184352 or BI-D1870
(Figure 3D), indicating that the signal from ERK1/2 to RNA
expression is mediated by RSKs. For the 11 mRNAs we
validated, up-regulation by ET-1 was consistently inhibited by
either drug at all times [Figure 3E and results not shown
for Areg (amphiregulin), Dusp (dual-specificity phosphatase)
4, Dusp10, Ets1 (v-ets erythroblastosis virus E26 oncogene
homologue 1), Has (hyaluronan synthase) 2, Hmgcr (3-hydroxy-
3-methylglutaryl-CoA reductase), Klf (Kru¨ppel-like factor) 5 and
Ripk (receptor-interacting serine-threonine kinase)]. The second
largest group (40 RNAs, cluster 2) contained RNAs inhibited by
PD184352 with no significant effect of BI-D1870 (Figure 3F).
For the seven mRNAs selected for validation, up-regulation by
ET-1 was consistently inhibited by PD184352 and there was no
significant change with BI-D1870 at 1 h [Figure 3G and results
not shown for Fosb (FBJ murine osteosarcoma viral oncogene
homologue B), Klf4, Rnd3 (Rho family GTPase 3) and Plk2
(polo-like kinase 2)]. However, for most [e.g. Egr (early growth
response) 3 and Ptgs2 (prostaglandin-endoperoxide synthase 2)],
there was enhancement of the ET-1 response with BI-D1870
at the later times. For these RNAs, the primary signal for
up-regulation is mediated by ERK1/2 independently of RSKs,
although RSKs may negatively influence the response at the
later times. The third significant group (22 RNAs, cluster 3)
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Figure 2 Phosphorylation and nuclear signalling of RSKs in cardiomyocytes
(A) Cardiomyocytes were exposed to ET-1 or A61603 for the times indicated. Total extracts were immunoblotted with antibodies against total RSKs or RSKs phosphorylated on Thr573, Thr359/Ser363
or Ser380. Blots are representative of at least three experiments with independent myocyte preparations. (B) Densitometric analysis of the blots in (A). Data were normalized to the maximum values.
Results are means +− S.E.M. for three (ET-1) or five (A61603) experiments with different cardiomyocyte preparations. (C and E) Cardiomyocytes were unstimulated (Con), or exposed to ET-1, PE
or A61603 for the times indicated (C) or for 5 min (E). Cysotolic and nuclear proteins were immunoblotted with antibodies against phospho-RSK(Thr573) (P-RSKs) or total RSKs (T-RSKs). Blots
are representative of at least three experiments with different cardiomyocyte preparations. (D) Densitometric analysis of the blots in (C). The graphs on the left-hand side show data normalized to
the maximum values. The graphs on the right-hand side show the relative percentage in each fraction. Results are means +− S.E.M. for three experiments with different cardiomyocyte preparations.
*P < 0.05, #P < 0.01 and **P < 0.001 relative to zero time. (F) Immunoblots of nuclear proteins following stimulation with ET-1, A61603 or PE (5 min) using goat polyclonal antibodies against
RSK1 (sc-231) or RSK2 (sc-1430), or antibodies against phospho-ERK1/2 (P-ERKs) or total ERK1/2 (T-ERKs). The experiment was repeated twice with different cardiomyocyte preparations with
similar results. (G) Immunoblots of nuclear proteins following stimulation with ET-1 or A61603 using rabbit polyclonal antibodies against RSK1 (#9333) or RSK2 (#9340) or antibodies against
GAPDH or CREB. The experiment was repeated twice with different cardiomyocyte preparations with similar results. (H) Densitometric analysis of the data from (F) and (G). Results are means +− S.E.M.
for at least three observations with different cardiomyocyte preparations. *P < 0.01 and **P < 0.001 relative to zero time; #P < 0.01 relative to A61603 at the same time.
contained RNAs for which BI-D1870 enhanced the response
to ET-1, whereas PD184352 inhibited the response (Figure 3H,
cluster 3). For the six mRNAs validated from cluster 3, up-
regulation by ET-1 was consistently inhibited by PD184352 and
BI-D1870 enhanced the response [Figure 3I and results not shown
for Egr2, Lif (leukaemia inhibitory factor) and Nr4a (nuclear
receptor subfamily 4, group A)3]. Other RNAs did not cluster into
significant groups. Overall, ∼51% of the mRNAs up-regulated by
ET-1 required RSKs for up-regulation, whereas ∼29% required
ERK1/2, but not RSKs, for up-regulation. Approximately half of
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Figure 3 Regulation of cardiomyocyte gene expression by ERK1/2 compared with RSKs
(A) Cardiomyocytes were exposed to ET-1 (5 min) in the presence of indicated concentrations of BI-D1870. Samples were immunoblotted for phospho-GSK3α/β , phospho-ERK1/2 or total ERK1/2.
The experiment was repeated with similar results. (B) Cardiomyocytes were exposed to 10 μM BI-D1870 for the times indicated or ET-1 (5 min). Samples were immunoblotted for phospho- or total
ERK1/2. The experiment was repeated with similar results. (C) Cardiomyocytes were unstimulated (control), or exposed to PD184352 or BI-D1870 (70 min). RNA expression was determined using
Affymetrix rat exon 1.0 ST arrays. RNAs regulated by PD184352 and/or BI-D1870 alone were clustered according to inhibition or enhancement. Mean expression (n = 3) relative to the controls is
shown for each RNA (numbers in each cluster are indicated). (D, F and H) Cardiomyocytes were unstimulated (control), exposed to PD184352, BI-D1870 or ET-1 alone (1 h), or exposed to ET-1 in
the presence of PD184352 or BI-D1870. RNA expression was determined using Affymetrix rat exon 1.0 ST arrays. RNAs up-regulated by ET-1 were clustered according to effects of each inhibitor
(numbers in each cluster are shown). Results are means +− S.E.M. for RNAs in each cluster relative to controls. *P < 0.001 and **P < 0.01 relative to the control; †P < 0.001 relative to ET-1. (E,
G and I) Cardiomyocytes were exposed to ET-1 in the absence/presence of PD184352 or BI-D1870 and mRNA expression for selected transcripts analysed by qPCR. Results are means +− S.E.M.
(n = 4).
the latter mRNAs showed enhanced expression following RSK
inhibition.
Regulation of cardiomyocyte RNA expression by α1-AR agonists
Our previous studies of the regulation of gene expression in
cardiomyocytes focused on ET-1. However, α1-AR agonists also
promote cardiomyocyte growth [17] whilst activating ERK1/2
to a lesser degree than ET-1 (Figure 1). To compare the
effects of α1-AR stimulation with ET-1, we initially used
Affymetrix rat expression 230 2.0 arrays for transcriptomic
profiling of the response to PE over a prolonged time
course (2, 4 and 24 h). We identified 385 and 120 RNAs as
significantly up- or down-regulated respectively (Supplementary
Table S4 at http://www.biochemj.org/bj/450/bj4500351add.htm),
substantially less than the response to ET-1 (827 RNAs up-
regulated and 598 RNAs down-regulated; Supplementary Table
S5 at http://www.biochemj.org/bj/450/bj4500351add.htm; the
previously reported data for ET-1 [14] were reanalysed in the
present study in parallel with the data for PE). After 24 h,
178 RNAs were significantly and similarly changed by either
agonist, 156 RNAs exhibited significantly different responses
to the two agonists, 23 RNAs were significantly changed
only with PE, and 206 RNAs were significantly changed with
ET-1 (Figure 4A and Supplementary Table S6 at http://
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Figure 4 Regulation of the cardiomyocyte transcriptome by PE
Cardiomyocytes were exposed to PE or ET-1 for the times indicated. RNA expression profiling was performed using Affymetrix rat 230 2.0 microarrays (A and C) or Affymetrix rat exon 1.0 ST arrays
(B). (A) Heatmaps for transcriptional changes at 24 h clustered according to similarity of response to PE compared with ET-1 (range: cyan = − 2.5; black = 0; red = 2.5; log2 scale). Results are
means for n = 3 independent hybridizations of different samples each prepared from three cardiomyocyte preparations. (B) k-Means clustering of mRNAs regulated by PE at 0.5 or 1 h. (C) k-Means
clustering of RNAs regulated by PE at 2, 4 or 24 h. (B and C) Results (means for n = 3 hybridizations) are shown for each RNA. Numbers of transcripts in each cluster are in parentheses.
www.biochemj.org/bj/450/bj4500351add.htm). Thus, although
there is overlap in response, cardiomyocyte hypertrophy induced
by ET-1 or PE is associated with different gene expression
profiles. This presumably reflects variation in the early phase gene
expression. We therefore examined the earliest phase of gene ex-
pression (0.5 and 1 h) induced by PE compared with ET-1
using more comprehensive Affymetrix rat exon 1.0 ST arrays.
The overall response to PE at 0.5–1 h was less than that
induced by ET-1 with up-regulation of 159 (compare with
285 for ET-1) RNAs and down-regulation of 25 (compare
with 93 for ET-1) RNAs (Supplementary Tables S7 and S8
at http://www.biochemj.org/bj/450/bj4500351add.htm). As for
ET-1 [14], PE-responsive RNAs were temporally regulated
(Figures 4B and 4C).
We selected 34 mRNAs (∼25% of protein-encoding transcripts
significantly up-regulated by PE over 0.5–1 h) for validation
experiments and further study by qPCR (Table 1). Overall, the
correlation between microarray and qPCR data was high with
a linear regression coefficient of 0.98 (Figure 5A). We used
2 μM PD184352 to determine the role of ERK1/2 activation
in the response to PE at 1 h. In some, although not all, cells
PD184352 may alter the energy balance and activate AMP kinase
[29,30]. In cardiomyocytes we did not detect phosphorylation
(i.e. activation) of AMPKα (AMP-activated protein kinase α)
by 2 μM PD184352, although AMPKα phosphorylation was
increased by 0.5 mM H2O2 (Figure 5B). As expected, PD184352
reduced the degree of ERK1/2 phosphorylation below basal
levels. Of the 31 mRNAs significantly up-regulated by PE at
1 h, only Has1 and Klf4 were insensitive to PD184352 and Atf3
(activating transcription factor 3) was inhibited to a small non-
significant degree (Figure 5C), whereas increased expression of
28 was significantly inhibited by PD184352 (Figures 5D, i and
5D, ii). Thus ERK1/2 signalling plays a significant role in the
PE-responsive cardiomyocyte transcriptome. We compared
the effects of PD184352 or BI-D1870 on the up-regulation of
selected mRNAs by PE with ET-1 (Figures 5E–5H). For all
mRNAs studied the inhibition of the response by PD184352 was
similar with either stimulus, whereas the relative effect of BI-
D1870 varied. For some the relative inhibition (e.g. Areg, Fosl1,
Dusp10 and Dusp4; Figure 5E) or enhancement (e.g. Egr1, Fos,
Nr4a1 and FosB; Figure 5F) by BI-D1870 was similar. However,
for seven of the 28 RNAs the effects of the inhibitors were
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Table 1 RNA expression data for PE and A61603
Cardiomyocytes were exposed to PE or A61603 for 0.5 or 1 h. RNA was extracted and analysed using Affymetrix microarrays or by qPCR. Results are expressed relative to the controls.
Microarray results are means for n = 3. The qPCR data are means +− S.E.M. (n = 3). Gene symbols are provided; accession numbers are provided in Supplementary Table S1(B) at
http://www.biochemj.org/bj/450/bj4500351add.htm Arc, activity-regulated cytoskeleton-associated protein; Ch25h, cholesterol 25-hydroxylase; Clcf1, cardiotrophin-like cytokine factor 1; Edn1,
endothelin 1; Gclc, glutamate-cysteine ligase, catalytic subunit; Gpr3, G-protein-coupled receptor 3; Rasd1, RAS, dexamethasone-induced 1; Rasl11b, RAS-like, family 11, member B.
PE (microarrays) PE (qPCR) A61603 (qPCR)
0.5 h 1 h 1 h 0.5 h 1 h
Gene symbol Mean Mean Mean S.E.M. Mean S.E.M. Mean S.E.M.
Arc 2.67 2.76 6.05 1.38 24.50 4.16 28.25 2.14
Areg 1.33 1.79 5.36 0.48 1.62 0.14 6.67 0.92
Atf3 3.30 3.45 4.96 0.81 9.04 1.12 13.96 2.49
Ch25h 3.44 2.31 3.44 0.35 4.32 0.43 1.84 0.07
Clcf1 1.63 1.63 2.68 0.11 2.42 0.23 3.36 0.69
Dusp10 1.16 1.61 1.79 0.24 1.03 0.02 2.30 0.18
Dusp4 1.53 2.04 2.91 0.32 1.40 0.02 2.16 0.24
Dusp5 2.35 2.51 3.90 0.89 3.05 0.33 2.82 0.32
Edn1 2.22 1.38 2.11 0.38 2.66 0.16 2.04 0.21
Egr1 3.17 2.29 4.87 0.87 16.59 1.99 7.30 0.74
Egr2 5.15 3.45 6.08 0.73 14.46 1.77 6.47 0.90
Egr3 6.46 6.82 11.93 1.42 33.12 2.82 27.44 1.37
Fos 7.34 2.51 7.29 1.41 44.57 3.62 6.43 0.18
FosB 3.49 2.64 16.99 3.23 22.34 4.43 17.29 4.54
Fosl1 2.08 2.98 5.58 0.46 4.69 0.14 9.60 0.61
Gclc 1.45 1.99 2.91 0.41 1.40 0.10 2.26 0.27
Gpr3 1.36 1.83 2.89 0.72 1.91 0.03 5.79 0.90
Has1 3.37 3.42 7.05 1.10 4.19 0.42 2.78 0.21
Has2 3.84 4.77 8.35 1.37 2.10 0.21 4.76 0.78
IL11 2.15 2.25 8.29 0.42 4.37 0.61 5.50 1.35
Klf4 2.19 2.28 3.03 0.47 1.78 0.04 1.93 0.16
Lif 7.45 5.07 11.49 2.38 9.61 0.33 7.93 0.60
Myc 1.35 1.59 2.15 0.14 2.07 0.07 2.69 0.07
Nr4a1 19.17 19.23 34.94 4.81 29.73 1.93 24.18 2.20
Nr4a2 13.16 14.77 25.77 3.11 2.70 0.26 2.23 0.35
Nr4a3 10.40 11.64 73.74 16.49 19.66 2.38 28.59 3.88
Olr1 1.55 1.90 2.79 0.34 1.60 0.07 2.30 0.20
Pim1 1.75 1.21 1.38 0.19 2.00 0.12 0.98 0.07
Plk2 1.64 1.50 1.91 0.17 2.10 0.11 2.50 0.17
Ptgs2 5.23 3.38 4.70 0.43 5.86 0.68 4.15 0.54
Rasd1 2.41 1.24 1.47 0.15 1.55 0.24 0.86 0.13
Rasl11b 1.62 1.32 1.46 0.18 1.99 0.19 1.78 0.07
Rgs2 4.93 4.09 6.87 0.88 2.95 0.23 4.62 0.36
Sik1 3.43 4.05 7.33 0.74 2.35 0.05 2.69 0.13
qualitatively different for the two agonists. For Egr2, Lif , Olr1
[oxidized low-density lipoprotein (lectin-like) receptor 1], Nr4a3
and Nr4a2, up-regulation of mRNA expression by ET-1 was
enhanced by BI-D1870 with no significant effect of BI-D1870
on the response to PE (Figure 5G and results not shown for
Nr4a2). For Rgs2 (regulator of G-protein signalling 2, 24 kDa)
and Klf4, up-regulation of mRNA expression by PE, but not ET-
1 was enhanced by BI-D1870 (Figure 5H). These data indicate
that differential activation of RSKs contributes to the different
RNA expression profiles induced in cardiomyocytes by ET-
1 compared with α1-ARs and are consistent with differential
regulation of nuclear RSKs, either because of the different
relative degrees of stimulation (Figure 2E) or selective nuclear
translocation of RSK2, but not RSK1, by α1-AR agonists
(Figures 2F–2H).
To determine the specific role of α1A-ARs in regulating
cardiomyocyte gene expression, cardiomyocytes were exposed
to A61603 (50 nM) and expression of the panel of 34 mRNAs
studied for validation of the PE response was examined by qPCR.
All were up-regulated by A61603 over 0.5–1 h (Figures 6A–6D
and Table 1). The relative increases in expression of four were
significantly greater and five were significantly less than PE.
However, the increase in expression of the remaining 25 mRNAs
was within 1.5-fold that induced by PE. Thus the principal
effect of PE on cardiomyocyte gene expression is mediated
through α1A-ARs, although other receptors may modulate the
response of selected mRNAs. As with PE and ET-1, there was
temporal regulation of gene expression by A61603 with some
mRNAs showing maximal stimulation at 0.5 h (Figure 6A), some
at 0.5–1 h (Figure 6B) and some over 0.5–1.5 h (Figure 6C),
whereas other mRNAs were not up-regulated until later times
(Figure 6D). To confirm the extent to which the response in
neonatal cardiomyocytes is representative of the intact heart,
we perfused adult rat hearts ex vivo with A61603 in the absence
or presence of PD184352 and examined the mRNA expression
of a subset of 25 mRNAs (for reasons unknown, but possibly
because of effects on the sinoatrial node or because of effects
on the vasculature, 5 or 10 μM BI-D1870 had a significant
adverse effect on cardiac contractility in the perfused heart system,
so we were unable to study its effects on mRNA expression).
As expected with a mixed population of unsynchronized cells,
the degree of up-regulation of all mRNAs in perfused hearts
was less, but 17 were significantly up-regulated (four showed
a small non-significant increase), the response of 13 of which
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Figure 5 Role of ERK1/2 compared with RSK signalling in the RNA expression response to PE
(A) Cardiomyocytes were exposed to PE (1 h). RNA expression was determined by qPCR or microarrays. Linear regression analysis was performed to compare mRNA expression determined by qPCR
(ordinate) compared with microarrays (abscissa) (axes are on a log2 scale). The regression coefficient (r) is 0.98. Results are means (relative to controls) for n = 3 different cardiomyocyte preparations.
(B) Cardiomyocytes were unstimulated, or exposed to 2 μM PD184352 or 0.5 mM H2O2 for the times indicated. Total extracts were immunoblotted with antibodies against phospho-AMPKα
(P-AMPK), total AMPKα (T-AMPK), phospho-ERK1/2 (P-ERKs) or total ERK1/2 (T-ERKs). The experiment was repeated with similar results. (C and D) Cardiomyocytes were exposed to PE in the
absence (closed bars) or presence (open bars) of PD184352 for 1 h. RNA expression was determined by qPCR. Data were normalized to GAPDH and then to the controls. Results are means +− S.E.M.
(n = 3). *P < 0.001, †P < 0.01 and ‡P < 0.05 relative to PE alone. (E–H) Cardiomyocytes were exposed to ET-1 or PE (1 h) in the absence (black bars) or presence of PD184352 (white bars) or
BI-D1870 (grey bars). Expression of selected mRNAs was measured by qPCR. Results are means +− S.E.M. for three (Rgs2 and Olr1) or four (other mRNAs) experiments with different cardiomyocyte
preparations. mRNAs are grouped according to relative effects of the inhibitors with each agonist. *P < 0.001, †P < 0.01 and ‡P < 0.05 relative to the respective agonist alone; **P < 0.001 and
#P < 0.05 relative to ET-1.
was inhibited by PD184352 (Figure 6E) consistent with the
cardiomyocyte response to PE (Figures 5C and 5D). Five were
not sensitive to PD184352 (Figure 6F), the greatest anomalies
being Lif and Ptgs2 that were sensitive to PD184352 inhibition
in cardiomyocytes exposed to PE (Figure 5C). Three showed no
change in expression in perfused hearts (Figure 6G), but these are
delayed and/or low level responses and the lack of synchronization
of the cells may be a factor. Overall the early gene expression
response to α1A-AR stimulation in adult intact rat hearts is largely
representative of that of neonatal rat cardiomyocytes in primary
culture.
RSKs are required for the increase in surface area induced by
ET-1 in cardiomyocytes
In neonatal cardiomyocytes, ET-1 increases myofibrillar
organization and content, in addition to increasing cell surface
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Figure 6 Regulation of cardiomyocyte and cardiac mRNA expression by A61603
(A–D) Cardiomyocytes were exposed to A61603 for the times indicated and mRNA expression was measured by qPCR. Results expressed relative to controls are means +− S.E.M. for four independent
experiments. Expression profiles are grouped according to temporal regulation. (E–G) Adult rat hearts were perfused retrogradely under control conditions (white bars), with A61603 alone (black
bars) or with A61 603 in the presence of PD184352 (grey bars). (E) mRNAs significantly up-regulated by A61603 with significant inhibition by PD184352. (F) mRNAs significantly up-regulated by
A61603 without significant inhibition by PD184352. (G) mRNAs not significantly up-regulated by A61603. Results are means +− S.E.M. for at least four hearts per condition. *P < 0.001, **P < 0.01
and @P < 0.05 relative to control; #P < 0.001, †P < 0.01 and ‡P < 0.05 relative to A61603 alone.
area. We compared the effects of PD184352 with BI-D1870 on
cardiomyocyte morphology by immunostaining with antibodies
against troponin T, a component of the myofibrillar apparatus
(Figure 7). PD184352 alone increased disruption of myofibrillar
organization compared with the unstimulated cells, whereas BI-
D1870 appeared to enhance myofibrillar organization to some
degree. Neither drug alone significantly affected the cell surface
area. ET-1 increased cardiomyocyte surface area, a response that
was reduced by PD184352 and inhibited by BI-D1870. Notably,
PD184352 particularly disrupted the myofibrillar organization
induced by ET-1.
DISCUSSION
Regulation of cardiomyocyte gene expression by ET-1 compared
with α1-ARs
Our previous transcriptomics studies focused on ET-1 and
the role of ERK1/2 signalling [13–15,20] because maximally
effective concentrations activate the entire pool of ERK1/2 in
cardiomyocytes (thus a maximal transcriptomics response should
be obtained), and rapid (within 2 min) nuclear localization of
phosphorylated ERK1/2 was detectable by immunostaining [12].
In contrast, α1-AR agonists such as PE do not activate the entire
pool of ERK1/2 and we could not detect a significant nuclear
signal for phospho-ERK1/2 using immunostaining (results not
shown). We now attribute this latter issue to the lower signal
being below the threshold for detection by immunostaining,
since nuclear phospho-ERK1/2 is detected in response to PE
or A61603 by immunoblotting (Figure 1). Additional concerns
for studies with PE related to possible contradictory signals
between different α1-AR subtypes and even whether there may
be interaction with β-ARs. However, the β-AR antagonist
propranolol did not enhance the activation of ERK1/2 by PE
(Figure 1A), indicating that the reduced level of activation did
not result from an inhibitory input from β-ARs. Furthermore,
activation profiles for ERK1/2 and RSKs by PE and A61603
(highly selective for α1A-ARs) were similar (Figures 1 and 2), and
mRNA expression studies conducted with PE and A61603 were
largely consistent (Figures 5 and 6, and Table 1). We therefore
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Figure 7 RSKs are required for the increase in size induced by ET-1
(A) Representative images of cardiomyocytes that were unstimulated (i, Control), or exposed
(24 h) to PD184352 (ii), BI-D1870 (iii), ET-1 (iv), or ET-1 plus PD184352 (v) or BI-D1870
(vi). Cells were immunostained for troponin T. The experiment was performed four times with
similar results. Scale bar = 100 μm. (B) Cardiomyocyte surface area was measured for each
condition, the average values being taken from each experiment as a single observation. Results
are means +− S.E.M. (n = 4). *P < 0.001 relative to the control, **P < 0.001 relative to ET-1
and #P < 0.01 relative to ET-1.
conclude that the responses to PE are mediated primarily through
α1A-ARs.
ET-1 and α1A-AR agonists each activate Gq-protein-coupled
receptors, signalling through protein kinase C and Ras to the
ERK1/2 cascade [17]. It is not clear, therefore, why gene
expression profiles induced by the two agonists, although
overlapping, are quite distinct (Figure 4 and Supplementary
Figure 8 Schematic diagram of the signal from ET-1 or PE/A61603 via
ERK1/2 to cardiomyocyte gene expression
ET-1, signalling through ETA (endothelin receptor type A) receptors, activates ERK1/2. The
nuclear signal is propagated via ERK1/2, RSK1 and RSK2 which phosphorylate and regulate
different panels of transcription factors (TFs). PE or A61603 signal through α1A-ARs to activate
ERK1/2 and the nuclear signal is propagated via ERK1/2 and RSK2, but not RSK1. This
divergence contributes to the overlapping, although distinct, transcriptomic profiles induced in
cardiomyocytes by these stimuli.
Tables S4–S8). Our data indicate that this does not result from
differential ERK1/2 signalling in the cytoplasmic and nuclear
fractions (Figures 1C and 1D). Instead, with RSKs playing
such a prominent role in the transcriptomic response to ET-1
(Figure 3 and Supplementary Table S3), differential regulation
of nuclear RSK1 by ET-1 and α1-AR agonists (Figures 2F–2H)
seems the most likely reason for the divergent profiles (Figure 8).
Further studies are necessary to dissect the downstream events
and identify the specific transcriptional regulators involved in
each response. The reason why PE and A61603 fail to stimulate
nuclear translocation of RSK1 also remains to be investigated.
One tantalizing observation is that ET-1 promotes accumulation of
catalytically active monophosphothreonyl-ERK1/2 in addition to
the classical dually phosphorylated form [12]. Since the phospho-
tyrosine residue is important in substrate recognition, the substrate
specificity of monophosphothreonyl-ERK1/2 may differ from
the dually phosphorylated form. Alternatively or additionally,
constraints with respect to location within the cytoplasm may
influence signalling specificity. Finally, it is possible that a
threshold effect might operate whereby lower levels of ERK1/2
activation are sufficient to activate RSK2, but an increased level
of activity is required for RSK1.
Nuclear trafficking of ERK1/2 and RSKs
In other cells, activation of ERK1/2 is associated with net
nuclear accumulation. ERK1/2 do not possess a classic nuclear
localization signal, and it is still unclear how ERK1/2 migrate
into the nucleus. Passive constitutive flux clearly plays a role
[24], potentially modulated by dimerization and/or scaffolding
proteins that retain inactive ERK1/2 in the cytoplasm [31].
Phosphorylation of ERK1/2 on additional sites may also
be important [32] and, in the heart, autophosphorylation
of ERK2(Thr188) may promote nuclear localization [33].
Unexpectedly, our immunoblotting experiments failed to reveal a
net translocation of total ERK1/2 to the nuclear compartment
in response to ET-1 or α1-AR agonists, despite accumulation
of phosphorylated ERK1/2 (Figures 1C–1E). This is unlikely to
result from poor quality preparations either of cardiomyocytes
or of nuclear proteins since we detect nuclear accumulation of
RSKs (Figure 2). Thus our data are consistent with a model
of constitutive, rapid and passive flux of ERK1/2 in and out of the
nucleus and there could be separate pools of ERK1/2, one of
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which is directed to the nucleus, whereas another is anchored
in the cytoplasm. We propose that the difference between
cardiomyocytes and other cells most likely reflects the relative
concentrations and precise components of the anchoring and
shuttling machinery, all of which remain to be defined. Unlike
ERK1/2, we detected very low levels of RSKs in the nuclear
compartment of unstimulated cells, with net translocation of
total RSKs to the nucleus following stimulation (Figures 2C–
2E). This is consistent with a model of cytoplasmic ERK1/2
phosphorylating cytoplasmic RSKs, enhancing their nuclear
translocation. Our observations are in agreement with recent
studies in other cells which indicate that activation of RSKs
reveals a bipartite nuclear localization signal resulting in nuclear
translocation [34].
The significant role of nuclear RSKs in regulating gene expression
Although activated RSKs were shown to translocate to the nucleus
in proliferating cells over 20 years ago [35], their contribution to
the transcriptomic effects of the ERK1/2 cascade has still not
yet been fully evaluated. In the heart, the focus has been almost
exclusively on their cytoplasmic role. Thus RSKs are implicated in
phosphorylation of Na+ /H+ exchanger 1 in the plasma membrane
and they phosphorylate cardiac myosin-binding protein C, a
regulatory component of the myofibrillar apparatus [36,37]. Other
cytoplasmic RSK substrates in cardiomyocytes include the pro-
apoptotic protein BAD (Bcl-2/Bcl-xL-antagonist, causing cell
death) [25] and GSK3α/β (Figure 3A). To our knowledge, ours
is the first study to demonstrate that RSKs play a significant role
in the nucleus and in regulating cardiomyocyte gene expression.
Interestingly, although the largest proportion of mRNAs up-
regulated by ET-1 required RSKs for up-regulation, many other
up-regulated mRNAs showed an enhanced response in the
presence of BI-D1870. An obvious explanation (since BI-D1870
activates ERK1/2, Figure 3B) is that it is a consequence of
enhanced ERK1/2 activity. We think this unlikely because all
RNAs in this group should then exhibit similar profiles and this
is not the case (Figures 3G and 3I). Secondly, BI-D1870 did
not enhance activation of ERK1/2 by ET-1 nor increase the
duration of the response (Figure 3A and results not shown).
Therefore, although enhanced ERK1/2 signalling induced by BI-
D1870 could stimulate RNA expression independently of agonist
stimulation (consistent with data in Figure 3C, cluster vii), it
cannot account for the enhanced stimulation induced by ET-1.
More probably, for some mRNAs, RSKs exert a negative effect on
expression, potentially via activation of inhibitory transcriptional
regulators, stimulation of microRNAs or enhancement of mRNA
degradation.
The role of RSKs in regulating gene expression has been
explored in a global context previously in cancer cells in relation
to cell migration [38]. That study used artificial and constitutive
activation of ERK1/2 over 24 h. The benefits of this approach
lie in the highly selective nature of the signal; however, although
this occurs in cancer cells, such high level constitutive activation
of the pathway is less common in other cells and tissues.
In cardiomyocytes exposed to ET-1 [14] or α1-AR agonists
(Figures 4 and 6), regulation of early gene expression occurs
according to temporal profiles with many RNAs exhibiting only
transient expression. This occurs in other systems including (as
recent examples) skeletal muscle exposed to insulin [39] and
macrophages exposed to pro-inflammatory stimuli [40]. Given
the difference in time point studied in our experiments (1 h) and
in the cancer cell system (24 h), and the nature of the two cell
types, it is perhaps not surprising that there is little overlap in the
RSK-responsive genes. However, in both systems and irrespective
of the degree of ERK1/2 signalling (i.e. potent activation of the
ERK1/2 cascade by ET-1 or lesser activation by α1-AR agonists),
RSKs clearly play a major role in regulating gene expression.
Despite the major contribution from RSKs to the transcriptomic
changes resulting from ERK1/2 activation, they are not the sole
means by which ERK1/2 promote gene expression and there is
a divergence, therefore, in the signal immediately after ERK1/2
activation. This appears to be functionally relevant given that
inhibition of RSKs with BI-D1870 inhibited the increase in cell
surface area induced by ET-1, but not the increase in myofibrillar
organization, whereas inhibiting the cascade with PD184352
caused myofibrillar disarray (Figure 7).
Influence of changes in immediate early gene expression on the
cardiomyocyte hypertrophic response
The principal aim of the present study was to gain insight into
the degree to which RSKs contribute to changes in mRNA
expression in cardiomyocyte hypertrophy. However, the genes
themselves are of prime importance. With an emphasis on early
times following stimulation, we identified different types of
modulator that are likely to propagate the hypertrophic response.
Thus, within the first few hours, classic immediate early genes
encoding transcription factors (e.g. Fos and Egr family members,
Atf3 and Myc) were up-regulated, in addition to orphan nuclear
receptors whose function remains to be established (e.g. Nr4a
family members). Some of these will regulate downstream gene
expression, whereas others are required to terminate immediate
early gene expression (e.g. Atf3 operates in a negative-feedback
loop with Egr1 [20]). We also identified changes in expression
of protein kinases [e.g. Sik1 (salt-inducible kinase 1) and Plk2]
and phosphatases (e.g. Dusps) indicating that innate signalling
networks are undergoing modification. Changes in the expression
of secreted growth factors [e.g. Areg, Lif and IL11 (interleukin
11)] and cell surface receptors (e.g. Olr1) are indicative of
changes in intercellular signalling. There were also changes in the
expression of channels and transporters, in addition to metabolic
enzymes, even at early times. Notably, many RNAs encoded
hypothetical proteins and proteins of no known function, and
the contribution of these to the overall hypertrophic response may
be immense.
Clearly it will be necessary to verify the degree to which
changes in mRNA expression are recapitulated at the protein
level. Nevertheless our data paint a picture of great flux and
dynamic change for the cardiomyocyte in this initial phase of the
response. This is presumably on-going in vivo, suggesting that
there are opportunities for modulating the response. Identifying
the optimum points for intervention will require a systems biology
approach to develop our understanding of the signalling and gene
expression networks within cardiomyocytes and other cardiac
cells, in addition to the communication networks that operate
between them. In the present study we take the first steps by
generating the data required for such an approach.
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